| Role of macrophage targeting in the antitumor activity of trabectedin | Cancer Cell | 2013 | 568 |
| Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy | Journal of Clinical Oncology | 2004 | 247 |
| Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem | Natural Product Reports | 2009 | 245 |
| Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production | Cancer Research | 2005 | 234 |
| Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B | Organic Letters | 2000 | 223 |
| Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells | Cancer Research | 2010 | 214 |
| Conjugate addition reactions of carbon nucleophiles to electron-deficient dienes | Chemical Society Reviews | 2010 | 202 |
| Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action | European Journal of Cancer | 2001 | 192 |
| Thiocoraline, a new depsipeptide with antitumor activity produced by a marine Micromonospora. I. Taxonomy, fermentation, isolation, and biological activities | Journal of Antibiotics | 1997 | 180 |
| Deciphering the biosynthesis pathway of the antitumor thiocoraline from a marine actinomycete and its expression in two streptomyces species | ChemBioChem | 2006 | 146 |
| Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways | International Journal of Cancer | 2001 | 143 |
| Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors | Journal of Clinical Oncology | 2001 | 141 |
| Trabectedin, a drug acting on both cancer cells and the tumour microenvironment | British Journal of Cancer | 2014 | 138 |
| Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D | Cancer Research | 2006 | 135 |
| Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer | Gynecologic Oncology | 2011 | 132 |
| Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 | Leukemia | 2003 | 130 |
| Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells | Molecular Cancer Therapeutics | 2003 | 126 |
| Pachastrissamine, a cytotoxic anhydrophytosphingosine from a marine sponge, Pachastrissa sp | Journal of Natural Products | 2002 | 121 |
| Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta | Oncogene | 2002 | 118 |
| Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A | Science | 2021 | 117 |
| Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial | Annals of Oncology | 2011 | 116 |
| Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites | | 2007 | 116 |
| Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma | Annals of Oncology | 2012 | 110 |
| In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients | Annals of Oncology | 1998 | 109 |
| A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas | European Journal of Cancer | 2012 | 105 |
